---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-089147"
form_type: "8-K"
ticker: "CVKD"
cik: "0001937993"
company_name: "Cadrenal Therapeutics, Inc."
filed_at: "2026-08-13T20:30:17+00:00"
generated_at: "2026-08-13T20:32:31.161875+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cadrenal Q2 net loss narrows to $3.3M; Phase 2 CAD-1005 cuts thrombotic events >25%

## Summary
- Q2 2026 net loss of $3.3M vs $3.7M in Q2 2025; R&D expenses $0.7M vs $1.1M; G&A $2.6M vs $2.7M.
- Cash ~$4.2M as of early August 2026, expected to fund operations through Q1 2027; not sufficient for clinical trials.
- Phase 2 CAD-1005 data at ISTH 2026 Congress in Paris showed >25% absolute reduction in thrombotic events.
- Launched structured partnering process for CAD-1005, frunexian, and tecarfarin; pursuing out-licensing model.
- Private placement raised ~$3.0M gross proceeds, up to ~$5.8M more if warrants fully exercised.

## SEC filing metadata
- accession: 0001213900-26-089147
- form_type: 8-K
- ticker: CVKD
- cik: 0001937993
- company_name: Cadrenal Therapeutics, Inc.
- filed_at: 2026-08-13T20:30:17+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937993/000121390026089147/0001213900-26-089147-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937993/000121390026089147/ea0302042-8k_cadrenal.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-089147
- JSON: https://secwatch.observer/filing/0001213900-26-089147.json
- Plain text: https://secwatch.observer/filing/0001213900-26-089147.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.